GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Float Percentage Of Total Shares Outstanding

Allakos (STU:37Z) Float Percentage Of Total Shares Outstanding : 70.26% (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Allakos Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Allakos's float shares is 62.21 Mil. Allakos's total shares outstanding is 88.54 Mil. Allakos's float percentage of total shares outstanding is 70.26%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Allakos's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Allakos's Institutional Ownership is 20.12%.

Allakos Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Allakos's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=62.21/88.54
=70.26%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allakos (STU:37Z) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
AKBA STOK APLT VSTM ZVRA STRO GLUE IKNA OBIO QSI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ALLK:USA
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Website
https://www.allakos.com
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Allakos (STU:37Z) Headlines

No Headlines